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Apolipoprotein E (apoE) and apoE/amyloid-β (Aβ) transgenic (Tg) mouse models are critical to understanding apoE-isoform
eﬀects on Alzheimer’s disease risk. Compared to wild type, apoE
−/− mice exhibit neuronal deﬁcits, similar to apoE4-Tg compared
to apoE3-Tg mice, providing a model for Aβ-independent apoE eﬀects on neurodegeneration. To determine the eﬀects of apoE on
Aβ-inducedneuropathology,apoE
−/− micewerecrossedwithAβ-Tgmice,resultinginasigniﬁcantdelayinplaquedeposition.Sur-
prisingly,crossinghuman-apoE-TgmicewithapoE
−/−/Aβ-Tgmicefurtherdelayedplaquedeposition,whicheventuallydeveloped
in apoE4/Aβ-Tg mice prior to apoE3/Aβ-Tg. One approach to address hAPOE-induced temporal delay in Aβ pathology is an ad-
ditional insult, like head injury. Another is crossing human-apoE-Tg mice with Aβ-Tg mice that have rapid-onset Aβ pathology.
For example, because 5xFAD mice develop plaques by 2 months, the prediction is that human-apoE/5xFAD-Tg mice develop
plaques around 6 months and 12 months before other human-apoE/Aβ-Tg mice. Thus, tractable models for human-apoE/Aβ-Tg
mice continue to evolve.
1.Introduction
Alzheimer’s disease (AD) is the most common form of dem-
entia and represents a serious economic and social burden
worldwide.ThefamilialformofAD(FAD)iscausedbyauto-
somal dominant mutations that increase levels of the 42
amino acid isoform of the amyloid-beta 42 (Aβ42) peptide
[1, 2]. The primary genetic risk factor for AD is inheritance
oftheAPOE4geneforapolipoproteinE(apoE),comparedto
APOE3,wi t hAPOE2 reducing risk [3–5]. The mechanism(s)
by which apoE and Aβ aﬀect pathogenesis of the disease is
unclear (reviewed [3–5]). However, evidence suggests that
apoE may isoform-speciﬁcally modulate Aβ-induced neuro-
toxicity [4, 5]. To address potential mechanisms in vivo,s e v -
eral transgenic (Tg) mouse models have been developed to
assess the structural and functional interactions between
apoE and Aβ. However, each of these models has potential
drawbacks that aﬀect the interpretation and physiological
relevance of the results. This paper will summarize the cur-
rent models resulting from the introduction of human-
APOE into Aβ-Tg mice. The continued development and
characterization of both apoE and apoE/Aβ-Tg mouse
models is critical to understanding the apoE-isoform eﬀects
on AD pathology.
1.1. Amyloid-β. Traditional diagnosis of AD is based on
pathology that includes extracellular amyloid plaques, com-
posed primarily of Aβ42, intraneuronal neuroﬁbrillary tan-
gles, hyperphosphorylated tau, neuroinﬂammation, and
neuronal cell loss. Aβ is a 39–43 amino acid (4kDa) peptide
produced via sequential proteolysis of amyloid precursor
protein (APP) by β-secretase/BACE followed by γ-secretase
(composed of presenilins [PS] 1 and 2), to produce Aβ pep-
tides primarily 40 and 42 amino acids in length. Genetic and
experimental evidence indicates that Aβ42 is the cause of AD
pathogenesis [1, 2]: (1) FAD, although only 3–5% of all AD
cases is caused by autosomal dominant mutations in APP,
PS1,orPS2thatincreaselevelsofAβ42ortheAβ42:40ratio;
(2) Down syndrome is caused by trisomy of chromosome 21
(thelocationoftheAPPgene),andischaracterizedbyplaque
deposition and dementia by the age 40; (3) Aβ42 is neuro-
toxic in vitro and in vivo.A β, particularly the more toxic
Aβ42, aggregates to form a variety of higher-order assem-
blies including oligomers, protoﬁbrils, ﬁbrils, and amyloid2 International Journal of Alzheimer’s Disease
plaques [6]. Amyloid plaques themselves exist in diﬀerent
conformations including compact plaques (composed of a
dense Thioﬂavin-S- (ThioS-) positive core), neuritic plaques
(identiﬁed as ThioS-positive plaques surrounded by a ring of
dystrophic neurites), and diﬀuse plaques (characterized by
amorphous wisps of amyloid that lack a central core and are
not neurotoxic) [7–10]. While total plaque burden does not
directlycorrelatewithdementia[11],itisanindicationofin-
creased Aβ42 levels, and compact or dense core plaques may
be disease relevant [7, 12].
1.2. ApoE. ApoE is the only apolipoprotein synthesized
within the blood-brain barrier (BBB) and is the primary
apolipoprotein associated with lipoprotein particles in the
central nervous system (CNS), as peripheral apoE is unable
to cross the BBB or blood-cerebrospinal ﬂuid barrier. While
the majority of apoE in the CNS is secreted by glial cells,
particularly astrocytes, neuronal production of apoE has
been observed under speciﬁc pathological conditions [13].
CNS lipoproteins are critical for lipid homeostasis, particu-
larly as cholesterol and phospholipids are required for neu-
ronal growth, repair, and synaptogenesis (reviewed [3–5]).
In humans, three apoE polymorphic alleles exist (APOE2,
APOE3, and APOE4) which encode three protein isoforms
(apoE2, apoE3, and apoE4). Although human-apoE (h-
apoE) is a 299 amino acid protein, the three apoE-isoforms
diﬀer by a single amino acid substitution at residues 112 or
158: apoE2 contains Cys112,158, apoE3 contains Cys112Arg118,
and apoE4 contains Arg112,158 [5]. In the general population,
APOE3 is the most common allele (77%), followed by
APOE4 (15%) and APOE2 (8%). In contrast, 40% of AD
patients express at least one APOE4 allele. Compared to
APOE3, inheritance of one or two copies of the APOE4 allele
increases the risk for developing AD by 4- and 12-fold,
whereas APOE2 decreases risk by 2- and 4-fold [5, 14].
Amyloid plaque deposition is greatest in AD patients with
an APOE4 allele(s) [14]. In addition to AD, APOE4 is a
risk factor for cerebral amyloid angiopathy (CAA; amyloid
deposition in blood vessels) and impairs recovery from cere-
bral insults such as stroke, cerebral hemorrhage, and brain
injury [4]. While apoE knock-out mice (apoE
−/−)a n dh -
apoE-Tg models demonstrate that apoE aﬀects neuronal via-
bility independent of Aβ-induced neurotoxicity, the focus of
this paper is on the synergism between the h-apoE isoforms
and Aβ on neuropathology. To address the latter in vivo,
apoE/Aβ-Tg models were subsequently developed to speci-
ﬁcally address the isoform-speciﬁc eﬀects of h-apoE on Aβ
deposition.
2.Transgenic Mice Expressing
Human ApoE (Table 1)
SeveralapproacheshavebeenusedtomakeTgmousemodels
to assess the function of apoE. ApoE
−/− Tg-mice were ini-
tially used to help understand the role of apoE in the brain
[15, 16] although the homology between mouse (m-) and
h-apoE is 70%, and mice express only a single isoform, com-
parable to apoE4 at residues 112 and 158 [54]. ApoE
−/− mice
have been used as the background for several h-APOE-Tg
mouselines.Heterologouspromotershavebeenusedtodrive
the expression of h-apoE in glia or neurons. Examples
include glialﬁbrillaracidic protein (GFAP; glial) [22,55–57],
transferrin (neuronal) [58], platelet-derived growth factor
(PDGF; neuronal) [59], neuron-speciﬁc enolase (NSE; neu-
ronal) [15], and thymocyte diﬀerentiation antigen 1 (Thy1;
neuronal) [59]. However, these models have limitations in-
herent in the use of a heterologous promoter and speciﬁc to
apoE: (1) the expression of protein by a heterologous pro-
moter is not regulated as it would be by the endogenous pro-
moter; (2) the inserted copy number of the transgene
cannot be regulated by a traditional Tg mouse approach;
(3) while the cell-speciﬁc expression of apoE in the brain is
controversial [60–63], the majority of evidence suggests that
glia, not neurons, are the primary cell type to express apoE
[13, 64–67]; (4) by using the m-apoE
−/− background and in-
ducing apoE expression via CNS-speciﬁc promoters, lack of
peripheral apoE becomes a variable of potential importance
when interpreting results from these mice; (5) evidence sug-
gests that in both humans and apoE-TR mice, apoE4 levels
are signiﬁcantly lower than apoE2 or apoE3 [68–73]. Knock-
in or targeted-replacement (TR) mice were developed that
express h-apoE under the control of the endogenous mouse
promoter and provide an alternative to heterologous expres-
sion of h-apoE. In apoE-TR mice, the coding domain for
each of the h-APOE isoforms replaces the coding domain for
m-APOE. Thus, in apoE-TR mice, glial cells express h-apoE
in a native conformation at physiologically regulated levels,
and in the same temporal and spatial pattern as endogenous
m-apoE. Thus, the interpretation of apoE isoform-speciﬁc
results is determined by the nature of the apoE-Tg mouse
model.
As discussed, a number of apoE-Tg mouse models have
been developed with apoE expression under the control of
diﬀerentpromoters[74].ThegeneralphenotypesofapoE
−/−
mice and three examples of the most widely studied apoE-Tg
mice (GFAP-apoE, NSE-apoE, and apoE-TR) are brieﬂy dis-
cussed (Table 1).
2.1. ApoE−/−. Compared to wild type, apoE
−/− mice have
decreased excitatory transmission, spine density, and den-
driticlength[16–18].Thesechangesmayunderliebehavioral
deﬁcits, as apoE
−/− mice are cognitively impaired [15, 19,
20]. However, lack of peripheral apoE can have profound
eﬀects on plasma lipid homeostasis, potentially leading to a
number of confounding variables, including metabolic dis-
ease and increased risk for cardiovascular disease, compro-
mising the ability to compensate for oxidative stress or in-
ﬂammation, deﬁcits that can eﬀect the vasculature of the
brain. In addition, the relevance of these mice is unclear as
there are no apoE
−/− humans. ApoE
−/− provides the back-
ground for a number of the h-apoE-Tg mice.
2.2.GFAP-apoEMice. GFAPisanintermediateﬁlamentpro-
tein, expressed at high levels by glia in the CNS. To target
apoE expression to glia, mice expressing h-apoE under the
control of the GFAP promoter were crossed with apoE
−/−
mice [17, 22, 23]. At the cellular level, GFAP-apoE4 miceInternational Journal of Alzheimer’s Disease 3
Table 1: ApoE transgenic models. Summary of the eﬀects induced by deletion of mouse apoE (apoE
−/−) or the introduction of h-apoE
isoforms on markers of neuronal degeneration and behavior. Key: HC: hippocampus; CX: cortex; DG: dentate gyrus; ChAT: choline acetyl
transferase; ICH: intracerebral hemorrhage; LTP: long-term potentiation; TR: targeted replacement (knock-in); F: female; M: male; m:
month.
ApoE model [ApoE] Neurodegeneration Behavioral phenotype Gender eﬀects on
behavior References
ApoE
−/− NA
Spine density and
dendritic length:
WT > KO (HC/DG,
12m)
Water maze:
WT > KO (6 m, F and
M)
Water maze:
M > F( 6m ) [ 15–21]
ChAT:
WT > KO (HC, 6 m, M)
Anxiety vertical
exploratory:
KO > WT (6m, F)
GFAP-apoE Matched
Spine length and density:
E3 > E4 (HC, 12m)
Water maze:
E3 > E4 (6m, F)
Water maze:
M > F (apoE4 only) [17, 22–24]
Radial arm maze:
E3 > E4 (11–14m, M)
NSE-apoE Matched
Synaptophysin:
E3 > E4 (HC, 5m)
Water maze:
E3 > E4 (6m, F)
Water maze:M> F
(apoE4 only, 6m)
ChAT activity:
E3 > E4 = KO (12m): [25–27]
Tau phosphorylation:
E4 > E3 (9m)
Kainic acid induced
neurodegeneration
Synaptophysin and
MAP-2:
E3 > E4 = KO (CX, 5m)
[25]
ApoE-TR E2 ≥ E3 > E4
Spine density and length:
E3 > E 4( 1 ,3a n d1 2m )
Water maze/Active Y
maze avoidance:
E3 > E4 (15m, F)
Water maze:
M > F( 6a n d1 3m )
Dendritic length and
node number:
E3 > E4 (1m)
Anxiety elevated
platform:
E4 > E3 (6–8m, F)
EPSP interval:
E4/E4 > E2/E4 > E3/E3
(1m)
[18, 28–35]
LTP:
E3 > E4 (2–4m)
ICH:
E4 > E3 (15m+)
Vascular amyloid:
E4 > E3 (15m+)
show increased CA1 cellular atrophy and decreased spine
density compared to GFAP-apoE3 mice [75]. In addition,
compared to GFAP-apoE3 mice, GFAP-apoE4 mice demon-
strate impaired cognition and increased anxiety; common
symptomsinADpatients[17,23,24].Interestingly,cognitive
impairmentisevidentatanearlierageinfemalecomparedto
male GFAP-apoE4 mice [23, 24]. A limitation of this model
is that the eﬀect of apoE isoform on neuroinﬂammatory res-
ponses cannot be interpreted, as apoE is expressed under the
control of a promoter that is induced by neuroinﬂammation.
2.3.NeuronalapoEExpression. NeuronalapoEexpressionre-
mains controversial, although expression has been identiﬁed
under conditions of stress [25]. To investigate the role of
neuronalexpression,apoE-Tgmiceexpressingh-apoEunder
the control of the NSE promoter were crossed with apoE
−/−
mice [25–27]. Kainic acid was used to induce apoE expres-
sion in these mice and resulted in the protection of NSE-
apoE3 mice from age- and kainic acid-induced presynaptic
and dendritic degeneration compared to NSE-apoE4 mice
[25]. In addition, female NSE-apoE4 mice demonstrate im-
paired cognition compared to female NSE-apoE3 mice [25].
In contrast, male NSE-apoE4 mice do not exhibit cognitive
deﬁcits [15]. Thus, the eﬀect of apoE4 on cognition may be
modulated by gender. This is similar to the early develop-
ment of cognitive deﬁcits in GFAP-apoE4.
2.4. ApoE-TR. To investigate the function(s) of apoE in
a more physiologically relevant apoE-Tg model, apoE-TR4 International Journal of Alzheimer’s Disease
mice were developed to express each h-apoE isoform under
the control of the endogenous m-APOE promoter [28–35].
Although apoE protein levels in brain homogenates of these
micewereinitiallydescribedasbeingsimilarforeachh-apoE
isoform [32], subsequent analysis demonstrated that apoE4
levelsaresigniﬁcantlylowerinplasma,CSF,andbrainhomo-
g e n a t e st h a na p o E 2a n da p o E 3[ 28, 30], similar to the levels
of apoE isoforms in humans [68–73]. Compared to apoE3-
TR mice, apoE4-TR mice demonstrate decreased spine
densityanddendritelength,reducedexcitatorytransmission,
and long-term potentiation (Table 1). Again, similar to the
cognitive deﬁcits observed in female GFAP-apoE4 mice and
NSE-apoE4 mice, female apoE4-TR mice are cognitively
impaired compared to female apoE3-TR mice [31, 32].
However, male apoE3-TR and apoE4-TR mice are not signi-
ﬁcantly diﬀerent. Interestingly, both apoE3- and apoE4-TR
females are cognitively impaired when compared to apoE-
isoform-matched males.
3.ApoEinAβ Transgenic Models (Table 2)
3.1. Aβ-Tg. Although amyloid plaques are a hallmark of
AD, the mechanisms underlying Aβ-induced toxicity remain
unknown. To help determine the eﬀects of Aβ and amyloid
deposition on neurotoxicity in vivo,A β-Tg mouse models
have been produced that express human FAD mutations.
These models include but are not limited to: PDAPP
(APPV717F), Tg2576 (APPK670N,M671L), J9 (PS1M146V,L286V,
APPV717F), as well as 5xFAD (APPK670N,M671L,I716V,V717I,
PS1M146V,L286V)( r e v i e w e di n[ 2]). These Aβ-Tg mice express
either APP mutations alone (PDAPP, Tg2576) or in com-
bination with PS mutations (J9, 5xFAD). Plaque develop-
ment generally begins at 6 months of age in these mice (with
the exception of 5xFAD), and the onset of cognitive deﬁcits
is dependent on the model (e.g., PDAPP at 6 months,
Tg2576 at 9 months). Because the APPK670N,M671L mutation
is linked primarily to CAA, the Tg2576 mice also develop Aβ
depositionaroundbloodvessels,particularlyleptomeningeal
and cortical vessels. However, one limitation of Aβ-Tg
models is the relative lack of neuronal loss as observed in
AD (reviewed[76]) althoughthere are some exceptions (e.g.,
5xFAD [49], APPSLPS1KI, and TBA2 mice [76]).
3.2. ApoE−/−/Aβ-Tg. Initially, the eﬀect of apoE on Aβ de-
position was investigated using apoE
−/− crossed with Aβ-Tg
mice (Table 2). Speciﬁcally, apoE
−/− mice were crossed with
PDAPP [77–79] or Tg2576 mice [80]. In both models, the
absence of apoE signiﬁcantly delayed ThioS-positive plaque
deposition by 6 months and decreased Aβ levels in the
hippocampus and cortex, as measured biochemically from
brain homogenates and by Aβ immunoreactivity [42, 77]
(Table 2). APOE aﬀects plaque deposition in a gene-dose-
dependent manner, as plaque levels were intermediate
in apoE+/−/PDAPP compared with apoE+/+/PDAPP and
apoE
−/−/PDAPP mice [78]. In addition, the Aβ40 CAA pre-
sent in the Tg2576 mice was absent in the apoE
−/−/Tg2576
mice [80].
3.3. GFAP-apoE/Aβ-Tg. The initial studies demonstrating
that the lack of m-APOE delayed plaque deposition in Aβ-
Tg mice led to the question of what would be the eﬀect of
introducing h-APOE into apoE
−/−/Aβ-Tg mice (Table 2). To
initially addressthis issue,GFAP-apoEmicewascrossedwith
apoE
−/−/PDAPP mice [41, 42]. Surprisingly, the introduc-
tion of h-APOE did not result in the expected reduction in
the age of onset of Aβ pathology, rather the presence of h-
APOE furtherdelayedAβ deposition. Amyloid accumulation
is delayed from 6 to 12 months in apoE+/−/PDAPP mice, and
to15monthsinGFAP-apoE+/−/PDAPPmice(Table 2).Once
plaque pathology returned, the greatest plaque burden was
found in GFAP-apoE4/PDAPP mice, compared with GFAP-
apoE2/PDAPP and GFAP-apoE3/PDAPP mice. One poten-
tial confounding factor in these mice, as well as the NSE-
apoE mice described below, is the equal expression of the h-
APOE isoforms,incontrasttohumandatawhereinheritance
of an APOE4 allele results in lower apoE levels [68, 69, 73].
3.4. Neuronal apoE Expression/Aβ-Tg. To determine the
eﬀectofneuronalh-APOEexpressiononAβpathology,NSE-
apoE were crossed with J9 mice (PS1M146V,L286V,A P P V717F)
[81]. Similar to GFAP-apoE/PDAPP-Tg mice, the introduc-
tion of h-APOE to J9 mice delayed plaque pathology from 8
to 19 months, with deposition greater in the NSE-apoE4/J9
than NSE-apoE3/J9 [26].
3.5. ApoE-TR/Aβ-Tg. The physiologic advantages of using
apoE-TR mice to study the function(s) of apoE in vivo led
to the generation of apoE-TR/PDAPP [30]a n da p o E - T R /
Tg2576 mice [47]( Table 2). The resulting data conﬁrmed
thath-APOE delayedplaquedeposition.InapoE-TR/PDAPP
mice, plaque deposition was delayed from 6 months to 18
months of age. An apoE isoform-speciﬁc eﬀect on Aβ
pathology was also observed, with ThioS staining, Aβ im-
munoreactivity, and Aβ levels in brain homogenates highest
with apoE4 [30]. In Tg2576 mice, plaque deposition initiates
at 9 months of age, while in apoE-TR/Tg2576 mice there
is minimal plaque staining at 15 months. Interestingly, at
15 months, the isoform eﬀect in these mice is primarily on
CAA (E4 > E3), as amyloid deposition in the parenchyma is
minimal [47].
3.6. Addressing h-APOE-Induced Delay in Aβ Pathology. The
major drawback to the apoE/Aβ-Tg crosses described thus
far is the signiﬁcant h-APOE-induced delay in Aβ pathology.
For example, in apoE-TR/PDAPP mice, plaque deposition
is not identiﬁed until mice are ≥18 months of age (Table 2).
This substantial delay precludes timely analyses of apoE
iso-form-speciﬁc eﬀects on early aspects of Aβ pathology.
One approach to address this temporal delay is to introduce
an additional insult, such as traumatic brain injury (TBI)
[82], kainic acid [25], nitric-oxide-synthase-2- (NOS2-)
knock-out[83],orbyblockingAβ degradationvianeprilysin
in-hibition [84]. Although no amyloid deposition is present
in 12-month-old GFAP-apoE/PDAPP mice, TBI at 9 months
leads to amyloid deposition at 12 months [82], which is
greaterwithapoE4comparedtoapoE3.KainicaciddecreasesInternational Journal of Alzheimer’s Disease 5
Table 2: APOE in Aβ transgenic models. Genetic deletion of mouse apoE (apoE
−/−)f r o mA β-Tg mice delays amyloid deposition, which is
further delayed by the introduction of h-APOE into Aβ-Tg mice. ∗LaDu Lab unpublished observations.
Aβ pathology (age of onset)
Transgenic line 2–4 months 4–8 months 8–10 months 11–13 months ≥13 months Total Aβ levels
PDAPP
+/− [36–39]
Diﬀuse Aβ
staining:
hippocampus
cortex
ThioS
(moderate):
hippocampus
cortex
ThioS (heavy):
hippocampus
cortex
ThioS (heavier):
hippocampus
cortex
PDAPP
+/−×
apoE
+/− [40]
ThioS (low):
hippocampus
cortex
ThioS
(moderate):
hippocampus
cortex
PDAPP
+/−×
apoE
−/−[41]
Diﬀuse Aβ
staining:
hippocampus
Thios (low):
hippocampus
cortex
6, 12, 15, 18, and
21 months:
PDAPP
+/− >
PDAPP
+/−/apoE
−/−
PDAPP
+/−×
GFAP-apoE
+/−
[42]
Thios
(moderate):
hippocampus
E4 > E3 > E2
6, 12, 15, 18, and
21 months:
E4 > E3
PDAPP
+/+×
apoE-TR [43]
ThioS low:
hippocampus
E4 > E3 = E2
cortex
E4 > E3 > E2
3 and 12 months:
E4 > E3
Tg2576 [42, 44–46]
Thios (low):
hippocampus
cortex
ThioS
(moderate):
hippocampus
cortex
ThioS (heavy):
hippocampus
cortex
CAA-ﬁbrillar
(low):
leptomeningeal
and cortical
vessels
CAA-ﬁbrillar
(heavy):
leptomeningeal
and cortical
vessels
CAA-ﬁbrillar
(heavy):
leptomeningeal
and cortical
vessels
Tg2576 × apoE
−/−
[42]
Diﬀuse Aβ
staining:
hippocampus
cortex
12 months Tg2576
> Tg2576/apoE
−/−
Tg2576 ×
apoE-TR[47]
CAA-ﬁbrillar
(moderate):
leptomeningeal
vessels
E4 > E3
J9 mice [48]
ThioS
(moderate):
cortex
hippocampus
J9 X NSE-apoE
[26]
ThioS:
hippocampus
E4 > E3
5xFAD [49]
ThioS
(moderate):
hippocampus
cortex
ThioS (heavy):
hippocampus
cortex
∗5xFAD ×
apoE-TR [50–53]
ThioS (low):
hippocampus
cortex6 International Journal of Alzheimer’s Disease
synaptophysin and MAP-2 staining in apoE
−/− and NSE-
apoE Tg mice, with the eﬀect more pronounced with apoE4
than apoE3. Nitric oxide, produced by inducible NOS (enco-
ded for by the NOS2 gene), is an important signaling and
redox factor that plays a key role in neuroinﬂammation and
neurodegeneration [83]. NOS2−/− mice have been crossed
with multiple Aβ-Tg mouse models, and results demonstrate
increased tau phosphorylation and neuronal loss in
NOS2−/−/Aβ-Tg mice [83]. In the Tg2576/NOS2−/− mice,
AβdepositionishighercomparedtoTg2576mice.Inhibition
of neprilysin, an enzyme that degrades extracellular Aβ,w i t h
thiorphan, induces ﬁbrillization and deposition of Aβ and in
wild-type mice. Thiorphan treatment of apoE-TR mice leads
to aggregation of mouse Aβ 1w e e ka f t e rt r e a t m e n t ,w i t h
higher Aβ deposition in apoE4-TR compared to apoE3-TR
mice [84, 85]. Thus, thiorphan treatment of h-apoE-Aβ-Tg
mice represents a potential method of accelerating human
Aβ deposition.
An alternative method to address the h-APOE-induced
temporal delay in Aβ accumulation is to cross apoE-TR mice
with Aβ-Tg mice that have rapid-onset Aβ pathology, such
as 5xFAD [49], 3xTR [86, 87], APPSLPS1KI [88], APPPS1
[89], or TgCRND [90]. For example, because 5xFAD mice
develop plaques by 2 months, the prediction is that apoE-
TR/5xFAD-Tg mice develop plaques around 6 months and
12 months before other human-apoE/Aβ-Tg mice (LaDu
lab, unpublished observations and [50–53]). The approaches
described herein will lead to more tractable apoE/Aβ-Tg-
models to assess the apoE isoform-speciﬁc eﬀects on Aβ
pathology.
4. Concluding Remarks
ApoE is the greatest risk factor for AD. ApoE
−/− mice exhibit
neuronal and cognitive deﬁcits. Human apoE-Tg mouse
models demonstrate that, compared to apoE3, apoE4 in-
creases markers of neurodegeneration and cognitive impair-
ment. Initially, to determine the eﬀect of apoE on Aβ pathol-
ogy, Aβ-Tg mice were crossed with apoE
−/− mice, resulting
in a signiﬁcant delay in plaque deposition. Surprisingly, the
introduction of h-APOE to several apoE
−/−/Aβ-Tg mouse
models further delayed plaque deposition. This temporal
delay restricts the usefulness of the current apoE/Aβ-Tg mice
for investigating the process of Aβ accumulation and the
resulting neurotoxicity. To accelerate Aβ deposition, current
apoE/Aβ-Tg models could be treated with an additional
insult such as TBI, crossed with other Tg models of neuro-
degeneration (NOS2−/−) ,o rt r e a t e dwi t hd r u g st h a td e c r e a s e
Aβ degradation. Alternatively, the development of Aβ patho-
logy could be accelerated by crossing Aβ-Tg models with a
rapid onset of Aβ pathology, such as 5xFAD mice with apoE-
TR mice. Transgenic models such as these provide tractable
models for identifying biomarkers and the eﬃcient initial
validation of therapeutic targets.
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